Vitamin D: The Supplement Almost Everyone Should Consider

The supplement industry is worth $150 billion. Most of it is marketing. So when someone tells you that nearly everyone is low in vitamin D and nearly everyone should be supplementing it, your scepticism muscle should twitch. Broad problem, simple solution, buy this bottle — it’s the industry’s favourite playbook.

Except here’s the thing: this time, the claim has actual research behind it.

Vitamin D deficiency is genuinely common. The evidence supporting supplementation — for specific people, in specific circumstances — is among the strongest you’ll find in the supplement world. But “almost everyone should consider it” and “everyone needs it” are two very different sentences, and the space between them is where the interesting questions live. That’s where we’re going today.

Why So Many People Are Low

Vitamin D is a strange nutrient. Your body can make its own — but only when ultraviolet B radiation from sunlight hits bare skin. For most of human history, that wasn’t a design flaw. People lived outdoors. Now most of us work under fluorescent lights, commute in sealed metal boxes, and reach for SPF 50 the moment we see sky. Our biology hasn’t budged. Our lifestyles have sprinted in the other direction.

The numbers tell the story. A 2011 analysis of US national health data published in Nutrition Research found that 41.6% of American adults were deficient in vitamin D, defined as serum 25-hydroxyvitamin D levels at or below 50 nmol/L. Among Black Americans, the figure was 82.1%. Among Hispanic Americans, 69.2%.

And in Australia — a country that has literally built its tourism brand on sunshine — the Australian Bureau of Statistics reported in its 2011–2013 Health Survey that 23% of adults, roughly 4 million people, had vitamin D deficiency. Seventeen percent had a mild deficiency, 6% moderate, and just under 1% severe. Four million people, in the sunburnt country.

The pattern repeats across Europe. A 2016 standardised analysis published in the American Journal of Clinical Nutrition estimated that approximately 40% of Europeans have serum levels below 50 nmol/L, with rates climbing sharply in northern latitudes and winter months.

Risk factors extend well beyond geography. Office workers, shift workers, people with darker skin, older adults whose skin synthesises vitamin D less efficiently, people who cover most of their body for cultural or religious reasons, and anyone living south of about 35° latitude during winter — all face elevated risk. Here in Melbourne, UVB radiation is insufficient to produce meaningful vitamin D in skin between May and August. Four months where the sun can’t do the one job we need it to do.

The honest summary: deficiency isn’t a marketing invention. It’s a predictable consequence of how we live now.

Deficiency vs. Insufficiency: A Distinction Worth Your Time

Not all “low vitamin D” is the same, and this is precisely the point where conversations — and marketing — start to blur.

The standard blood test measures 25-hydroxyvitamin D, or 25(OH)D, the circulating form that reflects your body’s vitamin D status. Simple enough. But where to draw the line between “enough” and “not enough” depends entirely on who’s holding the pen.

The Institute of Medicine (now the National Academies of Sciences) set the threshold at 50 nmol/L (20 ng/mL). Below that: deficient. Above it: sufficient for bone health in 97.5% of the population. They defined 30 nmol/L (12 ng/mL) as the point of serious deficiency — where clinical problems like rickets and osteomalacia show up.

The Endocrine Society uses a different framework. They place deficiency below 50 nmol/L but set a preferred target of 75 nmol/L (30 ng/mL) or higher.

That gap between 50 and 75 nmol/L? That’s where a lot of people live — and where a lot of supplements get sold. Under one definition, those people are fine. Under the other, they’re insufficient. Same blood, same body, different conclusion depending on which guideline your practitioner follows.

This isn’t ivory-tower hairsplitting. It determines how many people get classified as “low” and, by extension, how large the market for supplementation appears. The IOM framework was designed with a population-health lens — what level prevents clinical disease? The Endocrine Society asks a different question — what level might be optimal for broader health outcomes?

Both positions have evidence behind them. Neither is dishonest. But the next time someone tells you that “80% of people are deficient in vitamin D,” it’s worth asking which definition they’re working from.

What the Research Actually Says

Bone Health: Evidence Grade B-

This is where the vitamin D story began — it helps the body absorb calcium, and without enough of it, bones weaken. Severe deficiency causes rickets in children and osteomalacia in adults. That much is settled science, and has been for nearly a century.

The more interesting question is whether supplementation prevents fractures in people who aren’t severely deficient. And here, the answer got considerably more complicated in 2018.

A major meta-analysis led by Bolland and colleagues, published in The Lancet Diabetes & Endocrinology, examined 81 randomised controlled trials and found that vitamin D supplementation did not prevent fractures or falls, and had no clinically meaningful effect on bone mineral density. The results held regardless of dose.

That’s a significant finding. It didn’t mean vitamin D doesn’t matter for bones — it plainly does, especially when someone is genuinely deficient. But it did suggest that handing supplements to people who aren’t deficient doesn’t provide additional skeletal benefit. The distinction between correcting a deficiency and chasing an optimal number appeared to be clinically real.

Verdict: Essential in genuine deficiency. For people with adequate levels, supplementation doesn’t appear to offer measurable bone protection.

Immunity: Evidence Grade B+

This is where the more recent — and, I’d argue, more interesting — evidence lives.

A landmark 2017 individual participant data meta-analysis published in The BMJ, led by Martineau and colleagues, pooled data from 25 randomised controlled trials involving over 11,000 participants. The headline finding: vitamin D supplementation reduced the risk of acute respiratory tract infections, with an adjusted odds ratio of 0.88. The number needed to treat was 33 — meaning for every 33 people supplemented, one respiratory infection was prevented.

Those are modest numbers in isolation. But the subgroup analysis told the more compelling story. Among participants with baseline 25(OH)D levels below 25 nmol/L — those who were genuinely deficient — the protective effect was substantially stronger. And the benefit was seen primarily with daily or weekly dosing, not with large intermittent bolus doses. How you take it appears to matter as much as whether you take it.

This makes biological sense. Vitamin D receptors exist on most immune cells, and the vitamin plays a documented role in both innate and adaptive immunity. The respiratory tract epithelium uses vitamin D to produce antimicrobial peptides. The mechanism isn’t speculative — it’s mapped.

Verdict: One of the better-supported immune benefits for any supplement, particularly for those with low baseline levels. Daily dosing appears to matter more than bolus supplementation.

Mood and Depression: Evidence Grade C+

Here’s where I need to slow down and be careful with language, because this is the kind of finding that gets oversimplified the fastest.

The association between low vitamin D and depression is well-documented. A 2013 systematic review and meta-analysis published in the British Journal of Psychiatry by Anglin and colleagues examined 31,424 participants and found a significant association between low vitamin D levels and depression.

But association is not causation, and vitamin D and mood are a textbook case of why that distinction matters.

People who are depressed tend to go outside less, exercise less, and eat differently — all of which could independently lower vitamin D levels. It’s entirely plausible that low vitamin D is a marker of depression rather than a driver of it. Or it could be both. Untangling that from observational data is genuinely difficult, and the researchers know it.

The intervention trials — where researchers actually give people vitamin D and measure mood changes — paint a mixed picture. Some trials show modest benefit, particularly in people with clinically low levels. Others show nothing. Study quality is variable, dosing regimens differ, and many trials weren’t designed with depression as a primary outcome.

Research suggests there may be a genuine mood connection for people who are deficient, but the evidence is not yet strong enough for confident claims.

Verdict: A plausible connection with some supporting evidence, but not yet robust enough for a high confidence grade. The association is clearer than the causation.

Cancer and Cardiovascular Disease: Evidence Grade C-

The VITAL trial — one of the largest randomised controlled trials of vitamin D ever conducted — was published in the New England Journal of Medicine in 2019 by Manson and colleagues. It enrolled 25,871 participants, gave half of them 2,000 IU of vitamin D3 daily, and followed them for a median of 5.3 years. This was the kind of trial the vitamin D world had been waiting for.

The primary findings: no significant reduction in invasive cancer incidence or major cardiovascular events.

However, a secondary analysis showed a reduction in cancer mortality that emerged after excluding the first two years of follow-up — suggesting that vitamin D might influence cancer progression rather than initiation. That’s an intriguing signal, but secondary analyses are hypothesis-generating, not proof. They tell researchers where to look next, not what to conclude now.

Verdict: The big trial didn’t deliver the results many had hoped for. The cancer mortality signal is worth watching, but it doesn’t constitute strong evidence yet.

Testing: What the Numbers Mean

If any of this has made you curious about your own levels, the test is straightforward: a blood draw measuring serum 25-hydroxyvitamin D. In Australia, GPs can order it, though Medicare rebate criteria apply — testing is typically covered for people at higher risk of deficiency.

Here’s how to read the results:

A few things worth noting. Levels fluctuate with the seasons — a test in August in Melbourne will look different from one in February. Single readings are snapshots, not verdicts. And because the “optimal” range is itself debated, a result of 55 nmol/L could be read as perfectly adequate by one practitioner and worth supplementing by another. Same number, different conversation.

Supplementation: What the Trials Use

Most of the positive research uses vitamin D3 (cholecalciferol) rather than D2 (ergocalciferol). A 2012 meta-analysis published in the American Journal of Clinical Nutrition by Tripkovic and colleagues found that D3 was more effective at raising serum 25(OH)D levels than D2.

Common dosages in clinical trials range from 1,000 to 4,000 IU daily. The Australian and New Zealand position statement on vitamin D suggests that adults at risk of deficiency may benefit from 1,000 to 2,000 IU daily, particularly during winter months. The tolerable upper intake level set by the IOM is 4,000 IU daily for adults.

Vitamin D is fat-soluble, so it’s typically better absorbed when taken with a meal containing some fat. It’s also worth knowing that because it accumulates in the body, toxicity is rare but possible at very high doses sustained over time. Cases in the literature generally involve intakes well above 10,000 IU daily for extended periods.

Who’s Most Likely to Be Low

Certain groups consistently show higher rates of deficiency in population studies:

• Office workers and indoor occupations — limited UVB exposure during peak hours
• People living at higher latitudes — in Australia, this means southern states during winter
• Older adults — the skin’s capacity to synthesise vitamin D declines with age
• People with darker skin — melanin reduces UVB absorption
• People who cover most of their skin — for cultural, religious, or sun-protection reasons
• People with obesity — vitamin D is sequestered in fat tissue, reducing bioavailability
• Those with malabsorption conditions — coeliac disease, inflammatory bowel disease, and others that impair fat absorption

If several of these apply, the probability of insufficiency increases substantially.

The Honest Picture

Vitamin D occupies an unusual position in the supplement landscape. It’s the rare case where the evidence for widespread deficiency is genuine, well-documented, and not manufactured by marketing departments. The case for supplementation is strongest in people who are actually deficient — where the data for immune function, bone health, and possibly mood is reasonably solid.

Where it gets overstated is in the leap from “deficiency is common” to “more is always better.” The VITAL trial is an important corrective here: in a general population with largely sufficient vitamin D status, supplementation didn’t move the needle on cancer or cardiovascular disease. The evidence supports correcting a problem, not optimising a number.

The most honest reading of the research is this: vitamin D supplementation is one of the more evidence-supported options available for people who are deficient or at high risk of deficiency. For everyone else, the benefits are less clear, and a blood test is a more useful starting point than a bottle.

Not a miracle. Not a scam. Somewhere in between — which, in the supplement world, actually counts as a win.

Found this useful? Forward it to someone who’s been wondering about the vitamin D bottle in their medicine cabinet.

Have a supplement you want researched? Reply to this email and tell me.

Sources Cited:

• Forrest KY, Stuhldreher WL. (2011). Prevalence and correlates of vitamin D deficiency in US adults. Nutrition Research, 31(1), 48–54.
• Australian Bureau of Statistics. (2014). Australian Health Survey: Biomedical Results for Nutrients, 2011–12. Vitamin D. ABS cat. no. 4364.0.55.006.
• Cashman KD, et al. (2016). Vitamin D deficiency in Europe: pandemic? American Journal of Clinical Nutrition, 103(4), 1033–1044.
• Bolland MJ, et al. (2018). Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. The Lancet Diabetes & Endocrinology, 6(11), 847–858.
• Martineau AR, et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. The BMJ, 356, i6583.
• Anglin RES, et al. (2013). Vitamin D deficiency and depression in adults: systematic review and meta-analysis. The British Journal of Psychiatry, 202, 100–107.
• Manson JE, et al. (2019). Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine, 380(1), 33–44.
• Tripkovic L, et al. (2012). Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. American Journal of Clinical Nutrition, 95(6), 1357–1364.

Disclaimer: This article is for general informational purposes only and is not a substitute for professional medical or dietary advice. Consult a qualified health professional before making changes to your diet, exercise routine, or supplement regimen.

Affiliate disclosure: This edition contains no affiliate links.